As fraction sizes of 1.8 to 5 Gy are used to treat rectal cancer in the clinic, the effect of p53 status in more radiosensitive HCT116 colorectal cancer cells was also studied in the dose range 0–8 Gy. Here, TP53 is linked to rectal cancer.